Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity

scientific article published on 12 October 2015

Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2015PLoSO..1040136K
P356DOI10.1371/JOURNAL.PONE.0140136
P932PMC publication ID4601692
P698PubMed publication ID26457809
P5875ResearchGate publication ID282812384

P50authorZsuzsanna JakabQ4024870
P2093author name stringViktória Nagy
András Gézsi
Csaba Szalai
Dániel J Erdélyi
Katalin Csordás
Nóra Kutszegi
Orsolya Lautner-Csorba
Gábor T Kovács
Ágnes F Semsei
Judit C Sági
Krisztina Míta Gábor
P2860cites workHypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemiaQ73589836
[Importance of the National Childhood Cancer Registry in the field of paediatric oncology care in Hungary]Q87811869
Pharmacogenetics, pharmacogenomics, and individualized medicineQ23919667
Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequenceQ24563210
Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migrationQ28189515
Characterization of ionotropic glutamate receptors in human lymphocytesQ28343936
Use of ?-asparaginase in childhood ALLQ29041017
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivityQ34400003
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseQ34400424
Genomic variants in exons and introns: identifying the splicing spoilersQ35787564
Genome-wide analysis links NFATC2 with asparaginase hypersensitivityQ35820373
Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunctionQ36279178
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.Q36608593
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemiaQ36918761
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitizationQ37770689
Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adultsQ38079075
Optimizing asparaginase therapy for acute lymphoblastic leukemiaQ38079114
The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cellsQ38192495
Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.Q38248280
Asparaginase in acute lymphoblastic leukemiaQ38285254
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.Q39835436
Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological studyQ44002855
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemiaQ45261834
Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.Q46241489
Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trialQ46355327
Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sampleQ46982053
A direct approach to false discovery ratesQ56622258
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemiaQ56999328
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapyQ59662755
In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemiaQ60054990
Glutamate Released by Dendritic Cells as a Novel Modulator of T Cell ActivationQ62399771
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectleukemiaQ29496
P304page(s)e0140136
P577publication date2015-10-12
P1433published inPLOS OneQ564954
P1476titleSubgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity
P478volume10

Reverse relations

cites work (P2860)
Q38735393HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia
Q64269386Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Q38895172Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia
Q64077129Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment
Q38688039Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations
Q92542001Precision Medicine in Lymphoma by Innovative Instrumental Platforms
Q48331843Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.

Search more.